方盛制药：瑞卢戈利片药物临床试验获批准

Core Viewpoint - Fangsheng Pharmaceutical (603998.SH) announced that its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., has received the clinical trial approval notice from the National Medical Products Administration for the development of the generic drug RuLuGoli tablets, which will be used for clinical trials in prostate cancer [1] Group 1 - The approval allows Fangsheng Jianmeng to proceed with clinical trials for RuLuGoli tablets [1] - The drug is aimed at treating prostate cancer, indicating a strategic focus on oncology within the company's product pipeline [1]